When treating a narrowed coronary artery, interventional cardiologists today have two powerful drug-based options beyond plain balloon angioplasty: the drug-eluting stent (DES) and the drug-coated balloon (DCB). Knowing when each is the right choice — and why — is one of the most important decisions in modern PCI.
For the past two decades, drug-eluting stents have been the backbone of coronary intervention. They are effective, durable, and backed by an enormous body of evidence. But stents have a limitation: they leave a permanent metallic implant inside the artery. For certain patients and lesion types, the drug-coated balloon offers something different — effective drug delivery without leaving anything behind. The concept is elegant: treat the artery, then leave.
How Each Technology Works
Drug-Eluting Stent (DES)
A drug-eluting stent is a small metallic mesh tube coated with an antiproliferative drug (usually everolimus or zotarolimus) embedded in a polymer. It is delivered on a balloon catheter, expanded at the site of the blockage, and left permanently in the artery. The drug slowly elutes from the stent over weeks to months, suppressing the excessive cell growth (neointimal hyperplasia) that would otherwise cause the artery to narrow again — a process called in-stent restenosis.
Modern third-generation DES are highly effective. Restenosis rates are below 5–10% in most lesion types, and they have dramatically improved the durability of PCI compared with the bare-metal stents of the 1990s.
Drug-Coated Balloon (DCB)
A drug-coated balloon (also called a drug-eluting balloon, DEB) is a standard angioplasty balloon coated with an antiproliferative drug — typically paclitaxel or sirolimus — on its surface. The balloon is inflated at the lesion site for 30 to 60 seconds. During that brief contact time, the drug is transferred from the balloon surface directly into the arterial wall. The balloon is then deflated and removed entirely, leaving nothing behind.
The key advantage is that the entire drug dose is delivered in a single, concentrated contact event. There is no polymer, no permanent implant, and no ongoing drug release. The artery is treated and then free.
"The drug-coated balloon is not a lesser stent — it is a different philosophy. The goal is to treat the disease without adding hardware. For the right patient, that is a significant advantage."
— Dr. Zaidoun Hajali, MD FSCAI FRCPWhen Is the DCB Preferred?
In-stent restenosis (ISR) is the strongest indication for DCB. When a previously placed stent narrows again due to tissue ingrowth, placing another stent inside it creates a compounding problem. The DCB treats the restenosis with drug delivery without adding another metallic layer — and the evidence here is strong, with DCB now a Class I recommendation in ESC guidelines for ISR.
Small vessel disease (reference diameter below 2.5mm) is another preferred DCB territory. Small vessels are poorly suited to stenting — stents in small arteries have higher restenosis rates and are technically more challenging. A well-prepared vessel treated with DCB can achieve comparable results without the implant.
High bleeding-risk patients benefit from DCB because the required duration of dual antiplatelet therapy (DAPT) is much shorter — typically one to three months rather than the six to twelve months required after DES. For patients who need surgery soon or who cannot tolerate prolonged blood thinning, this matters enormously.
When Is the DES Still the Right Choice?
For most de novo lesions — new blockages in previously untreated arteries — the DES remains the first choice. Long lesions, calcified segments, bifurcations, left main disease, and chronic total occlusions all require the structural scaffolding that only a stent can provide. The DCB cannot hold open a vessel with recoil, dissection, or severe calcium — it requires a well-prepared, stable vessel wall to work.
The preparation step is critical for DCB success. Before a DCB can be used, the vessel must be prepared with plain balloon predilatation to achieve an acceptable result — typically less than 30% residual stenosis with no flow-limiting dissection. If adequate preparation cannot be achieved, a stent is needed.
What Does the Evidence Say?
The AGENT IDE trial (2024) was a landmark moment for DCB in the United States — the first randomised trial to demonstrate non-inferiority of DCB versus DES in small vessel coronary artery disease. Earlier European data from the BASKET-SMALL 2 and PICCOLETO II trials had already shown comparable outcomes in small vessels. For in-stent restenosis, multiple trials and meta-analyses have established DCB as at least equivalent to DES, with less metal burden.
Ongoing trials are exploring DCB use in larger vessels and de novo disease more broadly. The technology is evolving — newer sirolimus-coated balloons may offer advantages over the older paclitaxel platforms in certain settings.
- DES remains the gold standard for most de novo coronary lesions — it provides scaffolding, drug delivery, and decades of evidence.
- DCB is preferred for in-stent restenosis (Class I ESC recommendation), small vessel disease, and high bleeding-risk patients.
- DCB leaves no permanent implant and requires shorter dual antiplatelet therapy — a meaningful advantage for selected patients.
- Good lesion preparation is mandatory before DCB use — the vessel must be adequately dilated first.
- The choice between DCB and DES should be made case-by-case, based on lesion characteristics, patient factors, and operator experience.
